Anti-GnRH vaccine Improvac suppresses estrus in 78% of adult queens, inducing ovarian cysts and uterine atrophy.
Background
Uncontrolled reproduction in domestic cats (Felis catus) contributes significantly to overpopulation and welfare issues, necessitating effective and humane population control strategies. Current methods primarily rely on surgical sterilization, which is invasive and may not be feasible for large-scale colony management or feral cat populations. Immunocontraception, specifically targeting the gonadotropin-releasing hormone (GnRH) pathway, offers a promising non-surgical alternative by inducing an immune response against GnRH, thereby inhibiting the reproductive cascade. This approach aims to provide a reversible or long-acting contraceptive solution without the risks associated with surgery.
Study Design
Researchers investigated the effects of the anti-GnRH vaccine Improvac on reproductive function in 12 colony-housed adult queens. The treated group (TRT, n=9) received 0.5 mL of Improvac via subcutaneous injection, while the control group (CON, n=3) received 0.5 mL of saline solution. Queens received two doses 30 days (D) apart. Animals were divided into four groups for ovariohysterectomy at different time points: G1 (CON, n=3) at 90 D, G2 (TRT, n=3) at 120 D, G3 (TRT, n=3) at 270 D, and G4 (TRT, n=3) at 330 D. Estrous activity was monitored through behavioral observation and vaginal cytology, with data analyzed using GLIMMIX statistical models.
Results
All CON queens consistently displayed signs of estrus every 12-20 days. In contrast, seven out of nine (n=7/9) TRT queens did not exhibit any signs of estrus until their scheduled ovariohysterectomy at 120 D (n=2), 270 D (n=2), or 330 D (n=3). However, two TRT queens (n=1 at 120 D, n=1 at 270 D) did display estrus signs after vaccination, specifically at D10 and D45, respectively. Clinical, hematological, and biochemical parameters in treated queens remained within species-specific reference ranges, indicating short-term tolerability. Subcutaneous tissue masses developed at vaccination sites after the first dose but were undetectable by the study's end. Histological analysis revealed no abnormalities in the endometrium or ovaries of control queens.
TRT animals, however, exhibited significantly altered follicular development, characterized by the presence of ovarian follicular cysts, and their endometrium predominantly showed atrophic changes, consistent with suppressed reproductive hormone activity.
Key Findings
- Improvac suppressed estrus in 7 out of 9 (78%) treated adult queens.
- All control queens displayed estrus every 12-20 days, while most vaccinated queens showed no estrus.
- Treated queens developed ovarian follicular cysts and uterine atrophic changes.
- Clinical, hematological, and biochemical parameters remained within normal ranges, supporting short-term tolerability.
- Subcutaneous masses at injection sites resolved by the end of the study.
Why It Matters
This study provides compelling evidence that the anti-GnRH vaccine Improvac effectively suppresses estrous cycles and induces significant morphological changes in the reproductive organs of adult queens. This offers a promising non-surgical alternative for feline population control, potentially reducing the need for traditional spaying and its associated surgical risks and costs. For large-scale animal welfare programs or managing feral cat colonies, a long-acting, injectable contraceptive could revolutionize current strategies. While the protocol involved two doses, further research is needed to determine the optimal dosing regimen and duration of effect for practical application, moving towards a single-dose or longer-interval protocol for widespread use. The observed ovarian cysts and uterine atrophy highlight the profound impact on reproductive physiology, which is the desired outcome for contraception.
improvac
anti-gnrh
immunocontraception
feline
cat
reproductive-control